Golimumab plus methotrexate in patients with rheumatoid arthritis aged  65 years and 65 years of age

an interesting study especially for older rheumatic patients than 60 years.

Biologics targeting tumor necrosis factor (TNF) are an effective therapy for reducing the inflammation and improving the signs and symptoms of rheumatoid arthritis (RA). Golimumab is a fully human monoclonal anti-TNF antibody and is available as a subcutaneous (SC) injection or an intravenous (IV) infusion.

Clinical Trials
NCT00973479